Approval · Notice of Compliance 15139 · 2014
POMALYST: Notice of Compliance 15139
Issued January 20, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15139
- Date
- January 20, 2014
- Company
- Celgene IncSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority-NAS
- Therapeutic class
- Antineoplastic agent; immunomodulatory agent
Products in this notice
Medicinal ingredients
- POMALIDOMIDE 1 MG per CAP
- POMALIDOMIDE 2 MG per CAP
- POMALIDOMIDE 3 MG per CAP
- POMALIDOMIDE 4 MG per CAP